Top Markets
Coin of the day
Perpetua Medical AB (publ) Perpetua Medical AB (publ)

Perpetua Medical AB (publ)

PERP-B
Kedudukan dalam Saham #35990
Perpetua Medical AB (publ) delivers a range of solutions and products in Sweden... Perpetua Medical AB (publ) delivers a range of solutions and products in Sweden specifically tailored for the application and management of injectable medications. Among its principal offerings is DrugLog, a system designed to mitigate errors in pharmacy medication dispensing. Another key product, WasteLog, serves as a device for analyzing and reconciling discarded and returned controlled injectable substances. Additionally, PrepLog, built upon the core technology of DrugLog, integrates with existing prescription or medication management systems to enable the verification of drug preparations. The company, which was established in 2007 and maintains its headquarters in Uppsala, Sweden, officially changed its name to Perpetua Medical AB (publ) in April 2024, having formerly been known as Pharmacolog i Uppsala AB (publ). Perpetua Medical AB (publ) operates as a subsidiary entity of Nolsterby Invest AB.
Harga Saham
$0.37305641
Disegerakkan terakhir: 2026-08-14
Modal Pasaran
$3.19M
Perubahan (1 hari)
-2.62%
Perubahan (1 tahun)
-22.98%
Negara
SE
Perdagangan Perpetua Medical AB (publ) (PERP-B)

Kategori

Pendapatan untuk Perpetua Medical AB (publ) (PERP-B)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Perpetua Medical AB (publ), pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Perpetua Medical AB (publ) dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US